Investment Thesis
Alaunos is a pre-revenue company with zero sales and $1M annual operating losses, facing critical cash depletion within 3-4 months at current burn rates. Without immediate capital injection or dramatic operational changes, the company faces potential insolvency. The slight improvement in loss trends (EPS improving 24.7% YoY) is insufficient to offset the existential liquidity crisis.
Strengths
- No long-term debt on balance sheet
- Current ratio of 1.63x provides short-term liquidity buffer
- Loss per share trend improving YoY (shrinking losses)
Risks
- Critical cash runway: $354K cash with $1M+ annual burn = ~3-4 months of operations remaining
- Zero revenue and 50% YoY revenue decline indicates no viable commercial operations
- Negative ROE (-78.1%) and ROA (-53.4%) demonstrate fundamental unprofitability
- Imminent need for emergency capital raise or dilutive financing
- Pharma sector with no disclosed revenue-generating products or pipeline value
Key Metrics to Watch
- Cash and equivalents depletion rate and runway to insolvency
- Capital raise activity and terms (Form D filings, shelf registrations)
- Quarterly burn rate and operating expense trends
- Any revenue-generating activities or partnership announcements
Financial Metrics
Revenue
0.0
Net Income
-1.0M
EPS (Diluted)
$-0.59
Free Cash Flow
-1.1M
Total Assets
1.9M
Cash
354.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-78.1%
ROA
-53.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.63x
Quick Ratio
1.63x
Debt/Equity
0.00x
Debt/Assets
31.6%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:32:19.718950 |
Data as of: 2026-03-31 |
Powered by Claude AI